Triglyceride-lowering target

Triglyceride lowering refers broadly to the pharmacological targeting of molecules that regulate plasma triglycerides—fat molecules carried mainly within very-low-density lipoproteins (VLDLs) and chylomicrons. Elevated plasma triglycerides contribute independently to cardiovascular disease risk and can cause pancreatitis at very high levels. Therapeutic strategies focus on enhancing the breakdown/removal of circulating TRLs via activation or modulation of key metabolic regulators such as peroxisome proliferator activated receptor alpha (PPAR-alpha), which controls genes involved in fatty acid oxidation; increasing activity/expression/functionality of lipoprotein lipase that hydrolyzes circulating TGs; inhibiting apolipoproteins like apoCIII that suppress LPL function; blocking angiopoietin-like proteins that inhibit LPL; reducing hepatic production/reesterification pathways contributing to VLDL secretion; among others. Approved drugs like fibrates act primarily through PPAR-alpha activation while newer agents under development target apolipoproteins or angiopoietic factors more directly. These approaches aim both at reducing acute risks from hypertriglyceridemia such as pancreatitis and long-term cardiovascular events linked with elevated remnant cholesterol particles derived from TRLs. This multi-target approach reflects the complex biology underlying plasma triglyceride regulation rather than one single canonical molecular entity named “Triglyceride lowering.” The field continues evolving rapidly with promising new therapeutics emerging.

Other names

hypertriglyceridemia treatmentlipid-lowering targetsfibrate targets

Key mechanisms include: - Activation of PPAR-alpha nuclear receptor leading to increased expression of LPL and decreased apoCIII expression → enhanced catabolism of VLDL/triglyceride-rich particles - Inhibition or suppression of apolipoprotein CIII which normally inhibits LPL → increased breakdown of TGs - Inhibition of angiopoietin-like proteins ANGPTL3/4/8 which inhibit LPL → dis-inhibition leads to increased TG hydrolysis - Reduction in hepatic synthesis/secretion or reesterification pathways for fatty acids into triglycerides by modulating gene expression related to lipid synthesis/fatty acid oxidation pathways